Three cases reported in the December issue of the Mayo Clinic Proceedings suggest to investigators that all patients being treated with pergolide should be evaluated with echocardiogram for valvular disease, and that the drug should be discontinued if the echo shows valvular lesions without other etiology.
The editorialist offers a perspective on these cases, which are disquietingly reminiscent of the fenfluramine/dexfenfluramine story. “The clinical, echocardiographic and pathologic findings in our three patients suggest that pergolide treatment may cause valvular disease,” senior author Raul Espinosa, MD, from the Mayo Clinic in Rochester, Minnesota, says in a news release
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!